Article Versions Notes

Uckun FM, Cogle CR, Lin TL, Qazi S, Trieu VN, Schiller G, Watts JM. A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Cancers. 2020; 12(1):74. https://doi.org/10.3390/cancers12010074

Uckun, Fatih M., Christopher R. Cogle, Tara L. Lin, Sanjive Qazi, Vuong N. Trieu, Gary Schiller, and Justin M. Watts. 2020. "A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia" Cancers 12, no. 1: 74. https://doi.org/10.3390/cancers12010074

Uckun, F. M., Cogle, C. R., Lin, T. L., Qazi, S., Trieu, V. N., Schiller, G., & Watts, J. M. (2020). A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Cancers, 12(1), 74. https://doi.org/10.3390/cancers12010074